BusinessHemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017By Nasdaq OMXAug 15, 2017, 12:30 PM UTC
BusinessHemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-ToleratedBy Nasdaq OMXAug 14, 2017, 12:30 PM UTC
BusinessHemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017By Nasdaq OMXAug 11, 2017, 2:21 PM UTC
BusinessHemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue SyndromeBy Nasdaq OMXAug 8, 2017, 10:08 AM UTC
BusinessHemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue SyndromeBy Nasdaq OMXAug 4, 2017, 12:30 PM UTC
BusinessHemispherx Updates Status of Immuno-Oncology Program in Pancreatic CancerBy Nasdaq OMXJul 10, 2017, 12:30 PM UTC
BusinessHemispherx Biopharma Repurposes Ampligen in Immuno-OncologyBy Nasdaq OMXMay 31, 2017, 4:04 PM UTC
BusinessHemispherx Biopharma Repurposes Ampligen in Immuno-OncologyBy Nasdaq OMXMay 31, 2017, 4:04 PM UTC
